|
Senti Biosciences, Inc. (SNTI) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Senti Biosciences, Inc. (SNTI) Bundle
Evaluate Senti Biosciences, Inc.'s financial outlook like an expert! This (SNTI) DCF Calculator provides pre-filled financial data along with the freedom to modify revenue growth, WACC, profit margins, and other crucial assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .1 | .4 | 2.3 | 4.3 | 2.6 | 4.1 | 6.7 | 10.8 | 17.5 | 28.3 |
| Revenue Growth, % | 0 | 363.53 | 481.47 | 87.08 | -40.25 | 61.71 | 61.71 | 61.71 | 61.71 | 61.71 |
| EBITDA | -21.4 | -22.7 | -39.7 | -70.6 | -61.3 | -4.1 | -6.7 | -10.8 | -17.5 | -28.3 |
| EBITDA, % | -25123.53 | -5763.71 | -1731.86 | -1647.9 | -2395 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .4 | 2.0 | 3.0 | 3.9 | 5.4 | 4.1 | 6.6 | 10.6 | 17.2 | 27.8 |
| Depreciation, % | 502.35 | 503.81 | 131.38 | 90.74 | 211.99 | 98.15 | 98.15 | 98.15 | 98.15 | 98.15 |
| EBIT | -21.8 | -24.7 | -42.7 | -74.5 | -66.8 | -4.1 | -6.7 | -10.8 | -17.5 | -28.3 |
| EBIT, % | -25625.88 | -6267.51 | -1863.25 | -1738.64 | -2606.99 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 17.8 | 30.5 | 56.0 | 98.6 | 35.9 | 4.1 | 6.7 | 10.8 | 17.5 | 28.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .3 | .5 | .6 | 17.7 | 2.6 | 4.1 | 6.7 | 10.8 | 17.4 |
| Account Receivables, % | 91.76 | 80.46 | 21.08 | 14.61 | 691.29 | 61.58 | 61.58 | 61.58 | 61.58 | 61.58 |
| Inventories | .0 | .0 | 2.6 | 3.3 | .0 | 1.5 | 2.5 | 4.0 | 6.4 | 10.4 |
| Inventories, % | 0 | 6.35 | 113.62 | 76.74 | 0 | 36.62 | 36.62 | 36.62 | 36.62 | 36.62 |
| Accounts Payable | 1.2 | .9 | 5.2 | 1.4 | 1.3 | 3.2 | 5.1 | 8.2 | 13.3 | 21.6 |
| Accounts Payable, % | 1408.24 | 231.98 | 226.41 | 31.96 | 48.81 | 76.15 | 76.15 | 76.15 | 76.15 | 76.15 |
| Capital Expenditure | -2.0 | -1.2 | -5.5 | -41.4 | -12.0 | -4.1 | -6.7 | -10.8 | -17.5 | -28.3 |
| Capital Expenditure, % | -2348.24 | -294.67 | -241.95 | -965.33 | -470.05 | -100 | -100 | -100 | -100 | -100 |
| Tax Rate, % | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 | -11.41 |
| EBITAT | -21.8 | -24.7 | -42.7 | -74.5 | -74.4 | -4.1 | -6.7 | -10.8 | -17.5 | -28.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -22.2 | -24.4 | -43.7 | -116.6 | -94.9 | 11.3 | -7.4 | -11.9 | -19.3 | -31.2 |
| WACC, % | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -42.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -32 | |||||||||
| Terminal Value | -626 | |||||||||
| Present Terminal Value | -445 | |||||||||
| Enterprise Value | -487 | |||||||||
| Net Debt | 2 | |||||||||
| Equity Value | -489 | |||||||||
| Diluted Shares Outstanding, MM | 4 | |||||||||
| Equity Value Per Share | -110.16 |
What You Will Get
- Comprehensive Financial Model: Senti Biosciences’ actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Customizable Growth Projections: Adjust essential parameters such as revenue growth, gross margin %, and R&D expenditures.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Analytics: Leverages Senti Biosciences’ actual financial data for accurate valuation assessments.
- Simplified Scenario Testing: Easily evaluate various assumptions and analyze results side-by-side.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Download: Obtain the pre-configured Excel file containing Senti Biosciences, Inc.'s (SNTI) financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various forecasts and instantly compare the results.
- Make Decisions: Leverage the valuation insights to inform your investment choices.
Why Choose This Calculator for Senti Biosciences, Inc. (SNTI)?
- Designed for Experts: A sophisticated tool utilized by researchers, investors, and biotech analysts.
- Comprehensive Data: Senti Biosciences’ historical and projected financials preloaded for precision.
- Flexible Scenario Analysis: Easily simulate various projections and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance to facilitate your calculations.
Who Should Use This Product?
- Investors: Accurately assess Senti Biosciences, Inc.’s (SNTI) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to SNTI.
- Consultants: Easily customize the template for valuation reports tailored to Senti Biosciences, Inc. (SNTI) clients.
- Entrepreneurs: Acquire insights into financial modeling practices used by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Preloaded SNTI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.